Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Osteosarcoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Osteosarcoma. Displaying page 3 of 4.
    EudraCT Number: 2020-002366-13 Sponsor Protocol Number: IB2020-02 Start Date*: 2021-12-20
    Sponsor Name:Institut Bergonié
    Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas
    Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001709-24 Sponsor Protocol Number: FIICGDTIC Start Date*: 2005-08-24
    Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS)
    Full Title: Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adulto
    Medical condition: Sarcomas de partes blandas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004465-32 Sponsor Protocol Number: 2011/386 Start Date*: 2011-12-12
    Sponsor Name:Dept. of Cardiothoracic & Vascular Surgery, Aarhus University Hospital, Skejby
    Full Title: Can post-operative treatment with parathyroid hormone enhance bone healing and quality of newly formed bone after sternotomy in cardiac surgery patients?
    Medical condition: Sternotomy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10051332 Surgical procedure LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001272-39 Sponsor Protocol Number: GP/C/02/SAR Start Date*: 2005-10-21
    Sponsor Name:GP-PHARM, S.A.
    Full Title: Estudio multicéntrico, prospectivo, abierto, no controlado en pacientes con edad igual o superior a 65 años para evaluar la eficacia y seguridad de Doxorubicina liposomal (Doxorubicina GP-Pharm) en...
    Medical condition: Sarcoma de partes blandas
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014889-26 Sponsor Protocol Number: EORTC 62091 Start Date*: 2011-12-15
    Sponsor Name:EORTC (European Organisation for Research and Treatment of Cancer)
    Full Title: TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Ti...
    Medical condition: Histologically proven advanced and/or metastatic malignant soft tissue sarcoma intermediate/high grade, excluding the following tumor types :  Well-differentiated liposarcoma  Embryonal rhabdomyo...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) HU (Completed) DK (Completed) AT (Completed) NL (Completed) SK (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002359-39 Sponsor Protocol Number: 213406 Start Date*: 2020-09-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS
    Medical condition: Recurrent or refractory solid tumour
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002231-92 Sponsor Protocol Number: AP23573-04-202 Start Date*: Information not available in EudraCT
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma
    Medical condition: Metastatic and/or unresectable soft tissue or bone sarcoma (excluding GIST).
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004045-16 Sponsor Protocol Number: ET18-272 Start Date*: 2019-03-14
    Sponsor Name:Centre Léon Bérard
    Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo...
    Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005219-36 Sponsor Protocol Number: B9E-MC-S378 Start Date*: 2006-03-06
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors
    Medical condition: Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001152-39 Sponsor Protocol Number: SSG XX Start Date*: 2024-05-21
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall
    Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004040-10 Sponsor Protocol Number: GEIS-52 Start Date*: 2017-02-24
    Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS)
    Full Title: Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas
    Medical condition: Soft tissue sarcoma (undifferentiated pleomorphic sarcoma, synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, angiosarcoma, epithelioid hemangiosarcoma, solitary fibrous tumor and ep...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005294-60 Sponsor Protocol Number: CRAD001C24114 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis...
    Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000522-58 Sponsor Protocol Number: NPM001 Start Date*: 2014-10-02
    Sponsor Name:Klinikum der Universität München
    Full Title: A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or ad...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003355-38 Sponsor Protocol Number: D0816C00025 Start Date*: 2019-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
    Medical condition: Solid Tumours
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001141-41 Sponsor Protocol Number: 08-C-0007 Start Date*: 2012-09-18
    Sponsor Name:National Cancer Institute NCI
    Full Title: A PHASE I STUDY OF IPILIMUMAB (ANTI-CTLA-4) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH TREATMENT REFRACTORY CANCER
    Medical condition: Sarcoma - Wilm's Tumor - Lymphoma - Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004039-19 Sponsor Protocol Number: GEIS-51 Start Date*: 2017-03-23
    Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS)
    Full Title: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression.
    Medical condition: Patients with advanced soft tissue sarcomas and osteosarcomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004529-27 Sponsor Protocol Number: 1216.18 Start Date*: 2007-07-09
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EO...
    Medical condition: patients with five different tumour entities will be included in the present trial: 1. squamous cell carinoma of the head and neck 2. breast cancer 3. ovarian cancer 4. soft tissue sarcoma 5. meanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000571-37 Sponsor Protocol Number: ET21-030 Start Date*: 2021-08-02
    Sponsor Name:Centre Léon Bérard
    Full Title: A multicenter, randomized, open-label phase II trial evaluating the association of Gadolinium-based nanoparticles (AGuIX®) with radiotherapy for the therapeutic management of patients with progress...
    Medical condition: Patients with metastatic renal cancer, melanoma or sarcoma, or with non-metastatic sarcoma (soft tissue, chondrosarcoma, osteosarcoma…), and with a progressive / recurrent inoperable musculoskeleta...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004486-17 Sponsor Protocol Number: A4021020 Start Date*: 2008-08-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORS
    Medical condition: Ewing's sarcoma family tumours
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Not Authorised) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004441-33 Sponsor Protocol Number: MK-7902-013(E7080-G000-231) Start Date*: 2020-07-10
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
    Medical condition: Relapsed/Refractory pediatric solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) SE (Completed) HU (Completed) Outside EU/EEA BE (Completed) IT (Trial now transitioned) ES (Trial now transitioned)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 06:40:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA